Novo EVP says new data shows Wegovy stands out in obesity crowd
![Photo: Novo Nordisk / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13437735.ece/ALTERNATES/schema-16_9/doc7ia0auzwcdh568nudxa.jpg)
Novo Nordisk can celebrate obesity drug Wegovy, which is built on the GLP-1 analog semaglutide, as it has demonstrated a significant and sustained weight loss of 15.2 percent in a two-year study.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Wegovy weight loss results "very encouraging," says Novo EVP
For subscribers
Raising ambitions at Novo Nordisk an obvious move, says CEO
For subscribers